Is 0Q0Y undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6
Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0Q0Y when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0Q0Y (€6.19) is trading below our estimate of fair value (€13.81)
Significantly Below Fair Value: 0Q0Y is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0Q0Y?
Key metric: As 0Q0Y is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
The above table shows the Price to Sales ratio for 0Q0Y. This is calculated by dividing 0Q0Y's market cap by their current
revenue.
What is 0Q0Y's PS Ratio?
PS Ratio
0.8x
Sales
€12.73b
Market Cap
€10.07b
0Q0Y key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Sales vs Industry: 0Q0Y is good value based on its Price-To-Sales Ratio (0.8x) compared to the European Insurance industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is 0Q0Y's PS Ratio
compared to its
Fair PS Ratio?
This is the expected PS Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
0Q0Y PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio
0.8x
Fair PS Ratio
1.1x
Price-To-Sales vs Fair Ratio: 0Q0Y is good value based on its Price-To-Sales Ratio (0.8x) compared to the estimated Fair Price-To-Sales Ratio (1.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
The above table shows the analyst 0Q0Y forecast and predictions for the stock price in 12 month’s time.
Date
Share Price
Average 1Y Price Target
Dispersion
High
Low
1Y Actual price
Analysts
Current
€6.14
€6.64
+8.1%
11.3%
€8.00
€5.40
n/a
15
Nov ’25
€5.87
€6.27
+6.8%
11.5%
€7.65
€4.80
n/a
15
Oct ’25
€5.68
€6.28
+10.5%
11.5%
€7.65
€4.80
n/a
15
Sep ’25
€5.56
€6.26
+12.7%
11.7%
€7.65
€4.80
n/a
15
Aug ’25
€5.77
€6.11
+5.9%
14.1%
€7.50
€4.30
n/a
15
Jul ’25
€5.85
€6.10
+4.2%
14.4%
€7.60
€4.30
n/a
15
Jun ’25
€5.96
€6.06
+1.6%
15.3%
€8.00
€4.30
n/a
14
May ’25
€5.86
€5.90
+0.7%
12.0%
€7.00
€4.30
n/a
15
Apr ’25
€5.65
€5.84
+3.3%
11.6%
€7.00
€4.30
n/a
15
Mar ’25
€5.27
€5.88
+11.6%
11.3%
€7.00
€4.30
n/a
16
Feb ’25
€5.44
€5.76
+6.0%
11.5%
€7.00
€4.30
n/a
16
Jan ’25
€5.26
€5.49
+4.4%
12.0%
€6.75
€4.00
n/a
15
Dec ’24
€5.07
€5.48
+8.1%
12.0%
€6.75
€4.00
€6.04
15
Nov ’24
€4.62
€5.38
+16.6%
13.6%
€6.75
€3.60
€5.87
15
Oct ’24
€4.59
€5.45
+18.7%
13.3%
€6.75
€3.60
€5.68
14
Sep ’24
€4.76
€5.39
+13.2%
13.4%
€6.75
€3.60
€5.56
15
Aug ’24
€4.90
€5.38
+9.7%
14.1%
€6.75
€3.60
€5.77
14
Jul ’24
€4.64
€5.39
+16.2%
13.8%
€6.75
€3.60
€5.85
15
Jun ’24
€4.16
€5.33
+28.1%
15.0%
€6.75
€3.60
€5.96
14
May ’24
€4.11
€5.33
+29.9%
15.1%
€6.75
€3.60
€5.86
14
Apr ’24
€3.95
€5.38
+36.0%
15.5%
€6.75
€3.60
€5.65
14
Mar ’24
€4.93
€5.38
+9.1%
15.5%
€6.75
€3.60
€5.27
14
Feb ’24
€5.03
€5.29
+5.2%
14.7%
€6.75
€3.60
€5.44
14
Jan ’24
€4.80
€5.18
+8.0%
14.8%
€6.75
€3.50
€5.26
15
Dec ’23
€4.72
€5.19
+9.9%
14.8%
€6.75
€3.50
€5.07
15
Analyst Forecast: Target price is less than 20% higher than the current share price.